BioWorld Today profile of Cato BioVentures

Freedom From LPs Pays Off (PDF)

 

 

News About Cato BioVentures and Portfolio Companies

Click the following headlines to be taken to the news link or a PDF of the release.

 

Vistagen  12 November 2007

VistaGen Publishes Preclinical Data Supporting the Therapeutic Potential of AV-101 for Parkinson's Disease

Vistagen  6 November 2007

VistaGen Awarded $1.2 Million from NIH for Development of AV-101 for Neuropathic Pain, Parkinson's Disease and Epilepsy

Echo Therapeutics  05 October 2007

Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.

Echo Therapeutics  17 September 2007

CBV Portfolio Company Echo Therapeutics Announces Merger with Sontra Medical Corporation

Vistagen  30 January 2007

VistaGen's AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications -- IND to be Submitted to FDA in 2007

Jenken Biosciences  14 December 2006

Jenken Biosciences Receives FDA Clearance for Phase II Trial of Lead Compound

Vistagen  07 December 2006

Vistagen Therapeutics Annouces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson's Disease

Vistagen  30 November 2006

VistaGen Therapeutics and Sanwa Renew Embryonic Stem Cell Drug Discovery and Development Partnership Focused on New Diabetes Treatments

Cato BioVentures and Cato Research  09 October 2006

Cato Research and Cato BioVentures Establish Law and Entrepreneurship Program (PDF)

Cato BioVentures and Vistagen  23 March 2006

Vistagen Therapeutics and Cato BioVentures Sign Strategic Business Development Agreement for CNS Products

Cato BioVentures  06 December 2005

Cato BioVentures Seeks Strategic Marketing Partner for FDA-Approved NutreStore™

 

etrials  22 August 2005

etrials Announces Agreement to Become a Public Company Company

 

VistaGen 04 November 2004

VistaGen Secures More Key Embryonic Stem Cell Technology for Leading Edge Diabetes Research

 

VistaGen 03 August 2004

VistaGen Expands Board and Senior Management Prepares for Clinical Programs for Epilepsy and Pain

 

Cato BioVentures  18 June 2004

Drug OK Could Garner Cato Millions

 

VistaGen 12 January 2004

VistaGen Awarded NIH Research Grant for advanced preclinical development of lead epilepsy drug candidate

 

Cato BioVentures 13 February 2004

"Slow Growth Pays Big Dividends for CRO" (PDF)

 

VistaGen  and Artemis 19 November 2003

VistaGen Therapeutics Acquires Artemis Neuroscience, Inc.  – Enters Late-Stage Preclinical Development Program For Lead Epilepsy Drug Candidate (PDF)

 

Cato BioVentures and etrials  23 October 2003

Cato Venture Group Makes Strategic Investment in etrials (PDF)